Abstract | PURPOSE: MATERIALS AND METHODS: New Zealand White rabbits maintained on a high cholesterol/fat diet were subjected to balloon injury to the abdominal aorta. Ferumoxtran-10 or ferumoxytol (500 micromol/kg) was administered at 2, 4, and 8 weeks following injury. In vivo magnetic resonance imaging (MRI) was performed immediately prior to, immediately after, and 6 days post-contrast administration. Ex vivo MRI, histologic, and inductively coupled plasma-mass spectrometry (ICP-MS) iron analyses were performed on the excised vessels. RESULTS: The blood pool clearance of ferumoxytol (t(1/2) < or = 6 hours) was more rapid than that of ferumoxtran-10 (t(1/2) < or = 48 hours). Decreased in vivo MRI signal intensity in the abdominal aorta was observed at 2, 4, and 8 weeks following injury with ferumoxtran-10, but not with ferumoxytol. Consistent with these observations, ex vivo MRI signal intensity was decreased in the ferumoxtran-10 vessels, and to a lesser degree in the ferumoxytol vs. control vessels (- contrast agent). In contrast, in vitro macrophage phagocytosis of USPIO was four to six fold greater with ferumoxytol than with ferumoxtran-10. Additionally, the absolute iron content correlated with ex vivo MRI signal intensity in all vessels (r = -0.86, P < 0.0001). CONCLUSIONS: These data suggest that the exposure period of atherosclerotic plaque to USPIO rather than the kinetics of the USPIO uptake by plaque alone is a critical criterion for experimental design of in vivo studies.
|
Authors | April D Yancy, Alan R Olzinski, Tom C-C Hu, Stephen C Lenhard, Karpagam Aravindhan, Susan M Gruver, Paula M Jacobs, Robert N Willette, Beat M Jucker |
Journal | Journal of magnetic resonance imaging : JMRI
(J Magn Reson Imaging)
Vol. 21
Issue 4
Pg. 432-42
(Apr 2005)
ISSN: 1053-1807 [Print] United States |
PMID | 15779033
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright 2005 Wiley-Liss, Inc. |
Chemical References |
- Contrast Media
- Dextrans
- Magnetite Nanoparticles
- Oxides
- ferumoxtran-10
- Iron
- Ferrosoferric Oxide
|
Topics |
- Animals
- Arteriosclerosis
(diagnosis, metabolism)
- Contrast Media
(pharmacokinetics)
- Dextrans
- Ferrosoferric Oxide
- Iron
(pharmacokinetics)
- Macrophages
(metabolism, pathology)
- Magnetic Resonance Imaging
- Magnetite Nanoparticles
- Male
- Oxides
(pharmacokinetics)
- Rabbits
|